Point of Care Nano-Technology, Inc. (PCNT) Financial Statements (2026 and earlier)
Company Profile
| Business Address |
109 AMBERSWEET ROAD DAVENPORT, FL 33897 |
| State of Incorp. | |
| Fiscal Year End | July 31 |
| Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 4/30/2024 MRQ | 7/31/2023 | 7/31/2022 | 7/31/2015 | 7/31/2014 | 7/31/2013 | |||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash, cash equivalents, and short-term investments | 0 | 3 | 4 | 177 | 0 | |||
| Cash and cash equivalent | 0 | 3 | 4 | 177 | 0 | |||
| Prepaid expense | 5 | 3 | ||||||
| Total current assets: | 6 | 6 | 4 | 177 | 0 | |||
| Noncurrent Assets | ||||||||
| Intangible assets, net (including goodwill) | 119 | 123 | ✕ | |||||
| Intangible assets, net (excluding goodwill) | 119 | 123 | ||||||
| Total noncurrent assets: | 119 | 123 | ||||||
| TOTAL ASSETS: | 125 | 130 | 4 | 177 | 0 | |||
| LIABILITIES AND EQUITY | ||||||||
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts payable and accrued liabilities | 141 | 213 | 12 | 4 | 234 | |||
| Interest and dividends payable | ✕ | ✕ | ✕ | 12 | 4 | |||
| Accounts payable | 141 | 213 | ||||||
| Accounts payable and other accrued liabilities | ✕ | ✕ | ✕ | ✕ | ✕ | 234 | ||
| Debt | 95 | 26 | 26 | |||||
| Due to related parties | ✕ | ✕ | 100 | |||||
| Total current liabilities: | 141 | 213 | 107 | 130 | 260 | |||
| Noncurrent Liabilities | ||||||||
| Other undisclosed liabilities | 214 | 219 | 12 | |||||
| Total liabilities: | 141 | 213 | 320 | 349 | 272 | |||
| Equity | ||||||||
| Equity, attributable to parent, including: | (17) | (84) | (316) | (172) | (272) | |||
| Preferred stock | 0 | 0 | ||||||
| Common stock | 0 | 1 | 4 | 2 | 2 | |||
| Treasury stock, value | (1) | |||||||
| Additional paid in capital | 120,192 | 120,192 | 119,743 | 1,087 | 798 | |||
| Accumulated deficit | (120,979) | (120,276) | (120,063) | (1,261) | ||||
| Other undisclosed equity, attributable to parent | 770 | (1,072) | ||||||
| Total equity: | (17) | (84) | (316) | (172) | (272) | |||
| TOTAL LIABILITIES AND EQUITY: | 125 | 130 | 4 | 177 | 0 | |||
Income Statement (P&L) ($ in thousands)
| 4/30/2024 TTM | 7/31/2023 | 7/31/2022 | 7/31/2015 | 7/31/2014 | 7/31/2013 | ||
|---|---|---|---|---|---|---|---|
| Revenues (Revenues, Excluding Interest and Dividends) | 100 | ||||||
| Gross profit: | 100 | ||||||
| Operating expenses | (78) | (74) | (118,782) | (185) | (118) | ||
| Operating income (loss): | (78) | 26 | (118,782) | (185) | (118) | ||
| Nonoperating income (expense) | 10 | (128) | |||||
| Investment income, nonoperating | 10 | ||||||
| Interest and debt expense | (20) | (4) | (10) | ||||
| Income (loss) from continuing operations: | (78) | 36 | (118,802) | (189) | (256) | ||
| Income (loss) before gain (loss) on sale of properties: | ✕ | ✕ | 36 | (118,802) | (189) | (256) | |
| Net income (loss): | (78) | 36 | (118,802) | (189) | (256) | ||
| Other undisclosed net income (loss) attributable to parent | (100) | 128 | |||||
| Net loss available to common stockholders, diluted: | (78) | (64) | (118,802) | (189) | (128) | ||
Comprehensive Income ($ in thousands)
| 4/30/2024 TTM | 7/31/2023 | 7/31/2022 | 7/31/2015 | 7/31/2014 | 7/31/2013 | ||
|---|---|---|---|---|---|---|---|
| Net income (loss): | (78) | 36 | (118,802) | (189) | (256) | ||
| Comprehensive income (loss), net of tax, attributable to parent: | (78) | 36 | (118,802) | (189) | (256) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.